Moneycontrol
you are here: HomeNewsBusiness
Last Updated : Nov 28, 2017 10:47 AM IST | Source: PTI

Glenmark Pharma gets 7 observations from USFDA for Baddi unit

Glenmark said its Baddi unit contributes approximately 10 per cent of the revenue of the US sales.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Glenmark Pharmaceuticals today said the US health regulator has made seven observations after an audit at its Baddi manufacturing unit.

Glenmark said its Baddi unit contributes approximately 10 per cent of the revenue of the US sales.

"The Baddi unit of Glenmark Pharmaceuticals underwent an US FDA (US Food and Drug Administration) audit from November 6 -11, 2017. The USFDA issued seven observations through the form 483," Glenmark Pharmaceuticals said in a BSE filing.

Close

"We are in the midst of providing a comprehensive response to the observations and would be replying to the FDA shortly on the observations," it added.

The company, however, did not elaborate on the nature of observations.

The company's stock was trading 2.05 per cent down at Rs 579.10 apiece on the BSE in the morning trade today.
First Published on Nov 28, 2017 10:44 am
Sections